指南与共识泌尿男性生殖肿瘤

循证指南是否转化为临床实践?英格兰转移性激素敏感性前列腺癌治疗强化应用的国家人口学研究

Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England.
指南 / 共识 · Eur J Cancer · 2025-03-06

该研究通过国家癌症登记数据评估2018年1月至2022年12月英格兰29,713例转移性激素敏感性前列腺癌(mHSPC)患者的治疗强化使用情况,总体使用率为39.0%,且随年龄、合并症、衰弱、社会经济剥夺及黑人种族而降低,47个专科多学科团队(sMDT)间使用率从20.3%到53.7%不等。

要点

  • 29,713例mHSPC患者中治疗强化使用率为39.0%。
  • 75岁及以下男性治疗强化记录为59.8%(n=9184),75岁以上仅16.8%(n=2404)。
  • 47个sMDT间治疗强化使用率范围为20.3%至53.7%,老年患者差异更大。

核心结论

  • mHSPC患者中治疗强化可能存在使用不足,尤其是老年、黑人和社会经济剥夺患者。
  • 全国专科前列腺癌团队(sMDT)间实践存在显著差异,尤其在老年人群中,提示许多患者可能未接受最佳治疗。

研究设计与样本

  • 通过国家癌症登记识别2018年1月至2022年12月英格兰所有诊断为mHSPC的男性。
  • 使用医院和全身抗癌治疗数据评估诊断后六个月内治疗强化。
  • 多水平回归模型探讨治疗强化与年龄、合并症、衰弱、种族、社会经济地位、农村性和诊断年份等社会人口学因素的关联。
  • 评估英格兰负责协调前列腺癌诊疗的47个专科多学科团队(sMDT)间的差异。

主要发现

  • 29,713例mHSPC患者中治疗强化使用率为39.0%。
  • 治疗强化使用随年龄、合并症、衰弱、社会经济剥夺及黑人患者而降低(p始终<0.05)。
  • 75岁及以下男性中59.8%(n=9184)有治疗强化记录,而75岁以上男性仅16.8%(n=2404)。
  • sMDT间治疗强化使用率范围为20.3%至53.7%,老年患者尤其75岁以上者差异更大。

关键数值与推荐

  • 国际指南推荐对mHSPC联合多西他赛或雄激素受体通路抑制剂与雄激素剥夺治疗进行强化治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: International guidelines recommend treatment intensification combining docetaxel or androgen receptor pathway inhibitors with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer (mHSPC). However, evidence suggests underuse in many high-income countries. This study evaluates the use of treatment intensification in the English National Health Service (NHS) and explores patient and hospital-level factors associated with variation. METHODS: All men diagnosed with mHSPC in England between January 2018 and December 2022 were identified through the national cancer registry. Treatment intensification within six months of diagnosis was assessed using hospital and systemic anti-cancer therapy data. Multilevel regression models explored associations between treatment intensification and sociodemographic factors including age, comorbidities, frailty, ethnicity, socioeconomic status, rurality, and year of diagnosis. Variation among the 47 specialist multidisciplinary teams (sMDTs), responsible for coordinating prostate cancer care in England, was also evaluated. KEY FINDINGS AND LIMITATIONS: Among 29,713 mHSPC patients, treatment intensification use was 39.0 %. Treatment intensification use decreased with age, comorbidities, frailty, socioeconomic deprivation, and among black patients (p always < 0.05). 59.8 % (n = 9184) of men aged 75 or younger had a record of treatment intensification, compared to only 16.8 % (n = 2404) of men older than 75. The use of treatment intensification across sMDTs ranged from 20.3 % to 53.7 %, with greater variation in older patients, particularly those older than 75. CONCLUSIONS AND CLINICAL IMPLICATIONS: There is potential underuse of treatment intensification for mHSPC patients, particularly among older, black, and socioeconomically deprived patients. Significant variation in practice exists between specialist prostate cancer teams (sMDTs) nationally, especially in older populations, indicating that many patients may not receive optimal care.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dodkins J, Cook A, Mayne E, et al. Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England. Eur J Cancer. 2025. PMID: 40056561. doi:10.1016/j.ejca.2025.115335

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。